A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

ConditionImmunoglobulin A Nephropathy

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorNovartis Pharmaceuticals

About this trial

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.

Eligibility criteria

Qualifiers

Diagnosis of IgAN, regardless of symptom or treatment history

Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age

US-based with a proficient understanding of and ability to read the English language

Disqualifiers

None

Trial design

Treatments tested in this trial

No intervention
Other treatment
Iptacopan
Atrasentan

Treatment groups

300 Participants

are divided into 4 treatment groups

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov